Eli Lilly broke ground on a new $3.5 billion manufacturing facility in Pennsylvania for obesity and type 2 diabetes medicines, incorporating advanced technologies.
Eli Lilly and Company
PharmaEli Lilly broke ground on its U.S. manufacturing site in Lehigh Valley, PA, which will be dedicated to producing injectable medicines for obesity and type 2 diabetes and will combine technologies like machine learning, AI, and advanced data analytics.
Eli Lilly and Company on LinkedIn ↗Eli Lilly broke ground on a $3.5 billion manufacturing facility in Pennsylvania's Lehigh Valley to make next-generation obesity medicines.
PR Newswire — Health ↗
Since November 15, 2026
Eli Lilly and Company · Product AnnouncementGeneral Medicine Launches Memory Care Pathway to Speed Early Alzheimer's Disease Evaluation
Eli Lilly and Company · · LinkedIn GrantsFrom early grant support to this important milestone, the Yosemite team is proud to support…
Eli Lilly and Company · PartnershipPfizer’s Immunology Strategy Expands to In Vivo Cell Therapy With Starna Deal
Eli Lilly and Company · Product AnnouncementHLTH 2026: Teladoc Health's weight care program lets employers partially contribute to GLP-1 costs
Written for Andrew Elkind by Jordan Leahy with Clinical Terminal’s AI, from public reporting. Each line links to its source.